Biomunex Pharmaceuticals SAS has signed an exclusive license and exploitation agreement with Institut Curie for the development of a new class of antibodies.
Scientists from Sun Yat-sen University Cancer Center (SYSUCC) and affiliated organizations have reported data from a study that assessed the role of discs large-associated protein 5 (DLGAP5) in lung adenocarcinoma (LUAD).
Fibrocor Therapeutics Inc. has entered into a research and development collaboration with the Mcquade Center for Strategic Research and Development LLC (MSRD).
Organoids are 3D models created from human stem cells and resemble fetal tissues. In an article published in Nature Medicine on March 4, 2024, researchers from University College London provided details on the possibility of generating organoids from epithelial cells collected from amniotic fluid without terminating the pregnancy.
Cukurova University and the University of Alicante have synthesized new 2-(pyrrolidin-1-yl)thiazole compounds reported to be useful for the treatment of bacterial infections and tuberculosis.
Nextgen Bioscience Co. Ltd. describes new compounds acting as hypoxia inducible factor-1α (HIF-1α) or vascular endothelial growth factor receptor (VEGFR) inhibitors and reported to be useful for the treatment of stroke, cancer, obesity, asthma, glaucoma, inflammatory bowel disease, rheumatoid arthritis and Alzheimer’s disease, among others.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified new monoglyceride lipase (MGLL; MAGL) inhibitors reported to be useful for the treatment of pain, cancer, inflammatory bowel disease, endometriosis, asthma, mental diseases and neurological and renal disorders.
RSS
